Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) - PubMed (original) (raw)

Randomized Controlled Trial

. 2011 Oct 12;306(14):1549-56.

doi: 10.1001/jama.2011.1437.

Ian M Thompson Jr, Catherine M Tangen, John J Crowley, M Scott Lucia, Phyllis J Goodman, Lori M Minasian, Leslie G Ford, Howard L Parnes, J Michael Gaziano, Daniel D Karp, Michael M Lieber, Philip J Walther, Laurence Klotz, J Kellogg Parsons, Joseph L Chin, Amy K Darke, Scott M Lippman, Gary E Goodman, Frank L Meyskens Jr, Laurence H Baker

Affiliations

Randomized Controlled Trial

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Eric A Klein et al. JAMA. 2011.

Abstract

Context: The initial report of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found no reduction in risk of prostate cancer with either selenium or vitamin E supplements but a statistically nonsignificant increase in prostate cancer risk with vitamin E. Longer follow-up and more prostate cancer events provide further insight into the relationship of vitamin E and prostate cancer.

Objective: To determine the long-term effect of vitamin E and selenium on risk of prostate cancer in relatively healthy men.

Design, setting, and participants: A total of 35,533 men from 427 study sites in the United States, Canada, and Puerto Rico were randomized between August 22, 2001, and June 24, 2004. Eligibility criteria included a prostate-specific antigen (PSA) of 4.0 ng/mL or less, a digital rectal examination not suspicious for prostate cancer, and age 50 years or older for black men and 55 years or older for all others. The primary analysis included 34,887 men who were randomly assigned to 1 of 4 treatment groups: 8752 to receive selenium; 8737, vitamin E; 8702, both agents, and 8696, placebo. Analysis reflect the final data collected by the study sites on their participants through July 5, 2011.

Interventions: Oral selenium (200 μg/d from L-selenomethionine) with matched vitamin E placebo, vitamin E (400 IU/d of all rac-α-tocopheryl acetate) with matched selenium placebo, both agents, or both matched placebos for a planned follow-up of a minimum of 7 and maximum of 12 years.

Main outcome measures: Prostate cancer incidence.

Results: This report includes 54,464 additional person-years of follow-up and 521 additional cases of prostate cancer since the primary report. Compared with the placebo (referent group) in which 529 men developed prostate cancer, 620 men in the vitamin E group developed prostate cancer (hazard ratio [HR], 1.17; 99% CI, 1.004-1.36, P = .008); as did 575 in the selenium group (HR, 1.09; 99% CI, 0.93-1.27; P = .18), and 555 in the selenium plus vitamin E group (HR, 1.05; 99% CI, 0.89-1.22, P = .46). Compared with placebo, the absolute increase in risk of prostate cancer per 1000 person-years was 1.6 for vitamin E, 0.8 for selenium, and 0.4 for the combination.

Conclusion: Dietary supplementation with vitamin E significantly increased the risk of prostate cancer among healthy men.

Trial registration: Clinicaltrials.gov Identifier: NCT00006392.

PubMed Disclaimer

Figures

Figure 1

Figure 1. CONSORT Diagram

Figure 2

Figure 2

a: Cumulative Incidence of Prostate Cancer, Vitamin E vs. Placebo b: Cumulative Incidence of Prostate Cancer, Selenium vs. Placebo c: Cumulative Incidence of Prostate Cancer, Combination vs. Placebo

Comment in

Similar articles

Cited by

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. - PubMed
    1. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61. - PubMed
    1. Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology. 2011;77(5):1035–41. - PubMed
    1. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3 Pt 1):826–31. - PubMed
    1. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29(16):2185–90. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources